You are here
Health Systems Take Matters Into Their Own Hands
Generic shortages are draining hospital resources throughout the U.S. and in some cases imperiling inpatient treatment. The author considers the FDA’s performance and describes the approach some health systems are taking to create a solution.
Staying up to date with evolving pharmacotherapies is important to providing optimal therapies to patients. The authors present available evidence to support the role of novel and existing agents in treating type-2 diabetes.
The authors briefly review febrile neutropenia, describe risk assessment tools, and discuss treatment and prophylactic options for this serious complication.
Despite failures in late-phase trials, the pipeline of medications for Alzheimer’s disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.
Harm and death associated with methotrexate errors
CMS consideration of rebate overhaul elicits strong opinions
Approvals, new indications, regulatory activities, and more
Netarsudil ophthalmic solution (Rhopressa) for the reduction of elevated intraocular pressure; ertugliflozin (Steglatro) for adults with type-2 diabetes; and lutetium lu 177 dotatate (Lutathera) for certain gastroenteropancreatic neuroendocrine tumors
Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation